Federal grants to PDX Pharmaceuticals Inc
PDX Pharmaceuticals Inc in Portland, Oregon received $7.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Treatment Research, with $4.8 million. In fiscal 2025 it was awarded $1.4 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$7.1 million
- Awards4
- Awarded in FY 2025$1.4 million
- Largest award$2.6 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $2.3 million |
| FY 2022 | 1 | $101,639 |
| FY 2023 | 2 | $1.3 million |
| FY 2024 | 3 | $2.0 million |
| FY 2025 | 2 | $1.4 million |
Programs that fund PDX Pharmaceuticals Inc
| Program | Awards | Amount |
|---|---|---|
| Cancer Treatment Research | 2 | $4.8 million |
| Cancer Biology Research | 1 | $2.0 million |
| Cancer Detection and Diagnosis Research | 1 | $250,000 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $7.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| PLK1 and egfr targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer - lung cancer is the leading cause of cancer mortality, exceeding deaths from colon, breast, and prostate cancers combined. Resistance to chemo and targeted therapy is very common. Radiation therapy (RT) | Cancer Treatment Research | July 6, 2023 | $2.6 million |
| Novel nano-immunotherapy for treatment of non-small cell lung cancer - treatment of non-small cell lung cancer (NSCLC) typically, which requires a combination of many highly toxic drugs and radiation therapy, is not curative. Immune checkpoint inhibitors (ICIS) targeting PD-L1/PD-1 are causing a par | Cancer Treatment Research | September 23, 2021 | $2.2 million |
| In situ tumor vaccination with a nano-oligo therapeutic to induce whole-body antitumor immune response - significance/goal. Although immune checkpoint inhibitors (ICIS) have shown impressive outcomes in melanoma patients, the majority of patients fail to respond, mainly due to the absence of tumor-i | Cancer Biology Research | September 1, 2021 | $2.0 million |
| Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment - treatment of non-small cell lung cancer (NSCLC) requires a combination of many highly toxic drugs and radiation therapy, yet the 5-YEAR survival rate remains about 18%. Immune checkpoint inhibitors ( | Cancer Detection and Diagnosis Research | September 5, 2024 | $250,000 |
Questions people ask
How much federal grant money does PDX Pharmaceuticals Inc get?
$7.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives PDX Pharmaceuticals Inc the most?
The Department of Health and Human Services, with $7.1 million in 4 awards.
What is PDX Pharmaceuticals Inc's largest federal grant?
$2.6 million under Cancer Treatment Research, with its first action in the period on July 6, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund PDX Pharmaceuticals Inc?
Its largest are Cancer Treatment Research, Cancer Biology Research and Cancer Detection and Diagnosis Research.
Other grant recipients in Portland
- Oregon Health & Science University
- Tri-County Metropolitan Transportation District of Oregon
- Oregon Department of Housing & Community Services
- Mercy Corps
- Pacific States Marine Fisheries Commission
- Oregon Department of Environmental Quality
- Port of Portland
- Portland State University
Largest federal grant recipients in Oregon · Federal grants in Oregon